# Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

> **NCT00287235** · NA · COMPLETED · sponsor: **Vantive Health LLC** · enrollment: 70 (actual)

## Conditions studied

- Hepatic Encephalopathy
- Liver Failure
- Hepatitis, Chronic
- Liver Cirrhosis

## Interventions

- **DEVICE:** MARS
- **DRUG:** Standard Medical Therapy

## Key facts

- **NCT ID:** NCT00287235
- **Lead sponsor:** Vantive Health LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** 2003-11
- **Final completion:** 2004-04
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-03-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287235, "Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00287235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*